Table 2.

Changes in metabolic risk factors over 12 months of follow-up

Metabolic risk factors	Baseline	6 months	12 months	p value
HbA1c (mmol/mol) (n = 63)	77.3 ± 18.9	62.8 ± 16.1	60.9 ± 17.0	< 0.001**
Total cholesterol (mmol/L) (n = 53)	4.2 ± 1.1	3.7 ± 0.9	3.7 ± 0.9	< 0.001**
Triglycerides (mmol/L) (n = 53)	2.8 ± 1.7	2.6 ± 3.0	2.1 ± 1.4	0.15
HDL (mmol/L) (n = 53)	1.2 ± 0.5	1.1 ± 0.4	1.1 ± 0.4	0.22
ALT (IU/L) (n = 37)	30.3 ± 15.6	25.0 ± 12.5	25.5 ± 14.5	0.02*
Creatinine (μmol/L) (n = 59)	84.2 ± 32.2	85.8 ± 34.1	85.3 ± 36.4	0.75

This table summarises changes in metabolic risk factors at 6 and 12 months following initiation of semaglutide

Data presented as the mean ± SD

*Statistically significant at p ≤ 0.05, **Statistically significant at p ≤ 0.001, repeated-measures analysis of variance (ANOVA)